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Background: Elucidation of the molecular mechanisms by which cancer cells overcome hypoxia is potentially
important for targeted therapy. Complexation of hypoxia-inducible factors (HIFs) with aryl hydrocarbon receptor
nuclear translocators can enhance gene expression and initiate cellular responses to hypoxia. However, multiple
molecular mechanisms may be required for cancer cells to adapt to diverse microenvironments. We previously
demonstrated that a physical interaction between the ubiquitously expressed transcription factor Sp1 and HIF2 is a
major cause of FVII gene activation in poor prognostic ovarian clear cell carcinoma (CCC) cells under hypoxia.
Furthermore, it was found that FVII activation is synergistically enhanced when serum-starved cells are cultured
under hypoxic conditions. In this study, we investigated whether HIFs and transcription factor Sp1 cooperate to
activate multiple genes in CCC cells under conditions of serum starvation and hypoxia (SSH) and then contribute to
malignant phenotypes.
Methods: To identify genes activated under hypoxic conditions in an Sp1-dependent manner, we first performed
cDNA microarray analyses. We further investigated the molecular mechanisms of synergistic gene activations including
the associated serum factors by various experiments such as real-time RT-PCR, western blotting and chromatin
immunoprecipitation. The study was further extended to animal experiments to investigate how it contributes to
CCC progression in vivo.
Results: ICAM1 is one such gene dramatically induced by SSH and is highly induced by SSH and its synergistic
activation involves both the mTOR and autonomously activated TNFα-NFκB axes. We identified long chain fatty
acids (LCFA) as a major class of lipids that is associated with albumin, a serum factor responsible for synergistic
gene activation under SSH. Furthermore, we found that ICAM1 can be induced in vivo to promote tumor growth.
Conclusion: Sp1 and HIFs collaborate to activate genes required for the adaptation of CCC cells to severe
microenvironments, such as LCFA starvation and hypoxia. This study highlights the importance of transcriptional
regulation under lipid starvation and hypoxia in the promotion of CCC tumor growth.
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Cancer cells adapt to hypoxic microenvironments using
aberrant vasculature to enable tumor growth. Hypoxia-
inducible factors (HIFs) 1α and 2α are major transcrip-
tion factors required for adaptive responses to hypoxia.
HIFs in complex with the aryl hydrocarbon receptor
nuclear translocator (ARNT) can bind hypoxia response
elements (HREs) of target genes, where they act to en-
hance transcription [1]. This conventional mechanism
regulates genes such as VEGF and HO to improve rela-
tively mild hypoxic conditions [2,3]. However, many
tumor types, especially those of pancreatic and cervical
origin, are known to experience more severe hypoxic
stresses [4].
To respond to dynamic changes in hypoxic conditions
combined with variable nutrient, growth factor, and
hormone environments, tumor cells employ multiple
stress response mechanisms. In addition to HIF signaling,
endoplasmic reticulum (ER) stress followed by the un-
folded protein response (UPR) is another cellular response
involved in adaptation to severe hypoxia [3]. The UPR can
stimulate the transcription of additional genes required
for tumor survival and growth.
Mammalian target of rapamycin (mTOR) signaling is
also important for adaptation of cancer cells to hypoxia.
mTOR is a serine/threonine kinase and a regulator of
protein expression at the translational level [5]. mTOR
is activated via phosphorylation of its serine residues,
and its activation regulates levels of cellular nutrients,
energy availability, and growth factors [6]. In general,
mTOR becomes inactivated in hypoxic tumor tissues.
However, it is known that mTOR dysregulation promotes
the translation of HIF1 [5] and cooperates in responses to
hypoxic conditions, suggesting that the interaction be-
tween the HIF- and mTOR-signaling pathways is involved
in adaptation to hypoxia.
We previously demonstrated that the FVII gene, which
encodes blood coagulation factor VII (fVII) [7], can be
induced in ovarian clear cell carcinoma (CCC) cells in
response to hypoxia [8,9]. Ectopic expression of this pro-
coagulant promotes phenotypic changes in cancer cells
[8,10]. We also demonstrated that a physical interaction
between the ubiquitously expressed transcription factor
Sp1 [11] and HIF2 is a major cause of FVII activation in
CCC cells under hypoxic conditions [12]. Furthermore,
FVII activation is synergistically enhanced via a UPR-
independent pathway when serum-starved cells are
cultured under hypoxic conditions, explaining why throm-
bosis frequently occurs in CCC patients [12]. However,
little is known of the mechanisms underlying this
synergism.
Ovarian cancer is most the malignant of the gyn-
ecological neoplasms [13,14]. CCC in particular is highly
resistant to chemotherapy and has a poor prognosis[14]. We hypothesized that genes regulated by the
above-described Sp1-dependent mechanism are respon-
sible for adaptive responses to hypoxia with a severity
and/or duration that is characteristic of CCC tissues.
The aim of this study was to test this hypothesis. We
first tested whether multiple genes are activated under
hypoxia in an Sp1-dependent manner in CCC cells and
whether such transcriptional activations occur synergistic-
ally during serum starvation. We further investigated the
molecular mechanisms of synergistic gene activation, in-
cluding regulation by associated serum factors. The study
was further extended to investigate ICAM1 gene expres-
sion in vivo and its contribution to CCC progression.
Results
Sp1 and HIFs cooperate to activate multiple genes under
hypoxia
To identify genes activated under hypoxic conditions
in an Sp1-dependent manner, we first performed cDNA
microarray analyses. We used CoCl2 treatment under
normoxia, as we found previously that FVII induction
with this hypoxia-mimicking agent is higher than induc-
tion observed by maintaining cells in 1% O2 [12]. A CCC
cell line (OVSAYO) was first transfected with Sp1-siRNA
(Sp1-si) or negative control siRNA (NS-si) and then cul-
tured with (→CoCl2) or without CoCl2. Western blotting
showed that Sp1 knockdown did not affect HIF induction
(Figure 1a). Basal promoter activity of VEGF [15] and HO
[16] genes can be regulated by Sp1. However, the expres-
sion ratios of these HRE-dependent genes in CoCl2
treated cells vs. non-treated cells were largely unchanged
between control cells (NS-si→CoCl2 treatment/NS-si)
and Sp1-silenced cells (Sp1-si→CoCl2 treatment/NS-si
and Sp1-si→CoCl2 treatment/Sp1-si) (Figure 1b). In
contrast, expression of multiple genes in the presence
of CoCl2 was decreased by Sp1 silencing (Figure 1b and
Additional file 1: Table S1). Among them, the GAPDH
and TGFB genes have also been reported to be HRE-
dependent [17,18].
We tested whether genes activated in an Sp1-dependent
manner were also inducible under real hypoxia (1% O2) by
focusing on 4 genes (ICAM1 [19], KLF6 [20], JUN [21],
and AR [22]; Figure 1b), as their upregulation by direct
interactions with HIFs has not been reported and their
basal promoter activities are regulated by Sp1. Real-time
reverse-transcription polymerase chain reaction (RT-PCR)
analysis revealed that ICAM1, KLF6, and JUN genes were
weakly upregulated under hypoxia and in the presence of
fetal calf serum (FCS) (Figure 2a, FCS+ H) compared with
normoxic conditions (Figure 2a, FCS+ N). RT-PCR results
also showed that siRNA-mediated knockdown of HIFs,
particularly HIF1, impaired hypoxic induction of these
genes (Figure 2b). We confirmed by chromatin immuno-
precipitation (ChIP) that Sp1 and HIFs bind authentic
Figure 1 cDNA microarray analysis of genes activated by CoCl2 stimulation in an Sp1-dependent manner. a) western blot analysis of
lysates from cells transfected with non-specific (NS) or Sp1 siRNA. b) log2 ratio of mRNA levels transfected with NS- or Sp1-siRNAs and then
cultured for 24 h. Cells were further cultured for an additional 4 h under stimulation with CoCl2 (500 μM) or treatment with a vehicle control.
Figure 2 Sp1 and HIFs contribute to the synergistic activation of multiple genes in OVSAYO cells under SSH. a) Synergistic activation of
genes under SSH. N and H indicate normoxia (20% O2 for 16 h) and hypoxia (1% O2 for 16 h), respectively. Data shown represent the mean (n = 3) ± SD.
b) Activation of multiple genes under hypoxia is dependent on HIFs. Western blotting is also shown for HIFs. Data shown are the mean (n = 3) ± SD.
c) The ICAM1 promoter region and predicted Sp1 binding sites (ref. 19). PCR-amplicons generated in the reporter gene assay are shown in Additional file 2:
Figure S1a. Bold bars: mutated sites (Sp1-mut 1 and 2); underlined nucleotide sequences: regions deleted by mutagenesis. d, e) Luciferase reporter gene
assay. Plasmids were co-transfected with the indicated vectors, and luciferase activities were measured at 24 h post-transfection. Luciferase activities
measured in cells transfected with the empty vector were defined as 100%. Data shown are the mean (n = 3) ± SD. *P = 0.0018; **P = 0.075.
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(Additional file 2: Figure S1a). Furthermore, luciferase
reporter gene analysis revealed that the expression of
HIFs can activate the ICAM1 promoter more efficiently
than the KLF6 and JUN promoters (Figure 2c and d). Un-
like knockdown experiments targeting endogenous genes,
the effect on ICAM1 promoter activation was predomin-
ant for HIF2. Further experiments demonstrated that acti-
vation of the ICAM1 promoter by HIF2 is impaired when
a known Sp1 binding site is mutated (Figure 2c and e).
ChIP assay results showed that ARNT weakly bound to
the ICAM1 promoter region, but this binding was not
enhanced in response to CoCl2 treatment (Figure 3a and b).
However, HIF2 became bind the promoter region by
CoCl2 exposure (Figure 3c). As expected, ARNT was
found to bind the VEGF-HRE region in response to CoCl2
treatment (Figure 3a).
Previously, we demonstrated that the PAS domains of
HIF2 are required for its association with Sp1 [12]. Thus,
here we tested whether the PAS domains are important
for activation of the ICAM1 promoter by HIF2. Luciferase
reporter gene analysis revealed that HIF2-driven activation
of the ICAM1 promoter was largely impaired when the
domain-deleted HIF2 mutant (HIF2ΔPAS; 351–870
construct; ref. 12) was expressed instead of the full-length
HIF2 (Figure 3d and e). Collectively, these results
demonstrate that Sp1 and HIF2 can cooperate toFigure 3 Synergistic activation of the ICAM1 gene is independent of A
the indicated genes. Cells were cultured for 4 h under stimulation with Co
without immunoprecipitation. IgG: negative control using IgG. b) Results in
analysis of HIF2 binding to the ICAM1 promoter region. Cells were treated as
with the indicated expression vectors. After 24 h, expression of indicated prot
measured at 24 h post-transfection. Luciferase activities measured in cells tran
the mean (n = 3) ± SD. f) Western blot analysis of lysates from OVSAYO cells t
SSH for an additional 16 h. g) Real-time RT-PCR analysis of ICAM1 and VEGF ge
then cultured under SSH conditions for an additional 16 h. Data shown are thmediate ICAM1 induction in a HRE-independent
manner.
Sp1-dependent gene activation under hypoxia is
synergistically enhanced by serum deprivation
Serum starvation is a crucial component of ischemia
[23]. Hence, we next tested whether Sp1-dependent acti-
vation of the selected genes is enhanced under serum
starvation and hypoxia (SSH), as in the case of FVII [12].
We found that ICAM1, KLF6, and JUN, but not AR, are
synergistically activated under SSH. Notably, ICAM1 ex-
pression was dramatically induced (Figure 2a, FCS– H).
This robust expression under SSH may be characteristic
of CCC cells as this was also true in an additional CCC
cell line, OVISE (Additional file 2: Figure S1b). Other
ovarian cancer cells of different histological origin did
not exhibit such highly synergistic activation of genes
(data not shown). We found that the synergistic ICAM1
gene induction was decreased by Sp1 knockdown at
mRNA (Additional file 2: Figure S2a) and protein (Add-
itional file 2: Figure S2b) levels. This Sp1 dependence
was also confirmed for KLF6 and JUN induction, al-
though such SSH-specific effects were not observed for
VEGF expression (Additional file 2: Figure S2a).
The synergism involved in ICAM1 induction was evi-
dent. It has been reported that overexpression of ICAM1
protein correlates with cancer prognosis [24]. Thus, weRNT. a) ChIP analysis of ARNT binding to gene regulatory regions of
Cl2 (500 μM) or treatment with a vehicle control. I: Input control lysate
a) were quantitatively estimated by real-time PCR analysis. c) ChIP
in a). d) The ICAM1 promoter construct (Figure 2e) was co-transfected
eins was confirmed by western blotting. e) Luciferase activities were
sfected with the empty vector were defined as 100%. Data shown are
ransfected with non-specific (NS) or ARNT siRNA and then cultured under
ne expressions in OVSAYO cells transfected with NS or ARNT siRNA and
e mean (n = 3) ± SD.
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synergistic ICAM1 expression was decreased by silencing
HIFs (Additional file 2: Figure S2c). However, unlike in
hypoxic conditions with serum stimulation, both HIF1
and HIF2 contributed equally to synergistic ICAM1 in-
duction. Moreover, real-time RT-PCR analysis revealed
that synergistic activation of the ICAM1 gene under SSH
conditions is not affected by ARNT knockdown, while
VEGF expression was largely diminished (Figure 3f and g).
These results demonstrate that ICAM1 gene induction
under SSH can be mediated via ARNT-independent inter-
actions between Sp1 and HIFs within the gene promoter
region.
UPR does not contribute to synergistic ICAM1 activation
A UPR marker CHOP is induced in OVSAYO cells
cultured under SSH (Additional file 2: Figure S3a). Thus,
we tested whether expression of the ICAM1 gene under
hypoxia with or without FCS treatment was enhanced
by simultaneous treatment with the UPR-inducing agent,Figure 4 Involvement of mTOR in the synergistic activation of ICAM1
cells cultured under the indicated conditions for 16 h. The phosphorylation
ImageJ software. b) Effect of rapamycin on the synergistic activation of ICA
(n = 2) ± SD. c) Western blot analysis of HIF expression in OVSAYO cells cult
Effect of mTOR on the synergistic ICAM1 activation in OVSAYO cells transfe
compared with the vehicle control. Inset: western blot analysis of ICAM1 ex
under SSH for 24 h. e) Effects of mTOR on the expression levels of HIFs in
of KLF6 and JUN in OVSAYO cells. Cells were transfected with siRNAs as ind
16 h. Data shown are the mean (n = 2) ± SD.tunicamycin (Tun). Tun induced CHOP under hypoxia
with or without FCS (Additional file 2: Figure S3b and c)
and suppressed ICAM1 expression (Additional file 2:
Figure S3d and e). The expression levels of Sp1 and
HIFs were not significantly altered (Additional file 2:
Figure S3b), suggesting that the synergistic activation is
not mediated by the UPR, as is the case with FVII [12].
mTOR is involved in synergistic gene activation under SSH
Western blotting showed that mTOR activation was sup-
pressed in OVSAYO cells cultured under SSH, as phos-
phorylation at Ser2448 was decreased compared that
observed under non-SSH conditions (Figure 4a). We next
tested the requirement of mTOR for synergistic gene acti-
vation, as the active mTOR fraction remaining may func-
tion under SSH. Real-time RT-PCR revealed that ICAM1
activation under SSH conditions in OVSAYO cells was
diminished by treatment with the mTOR inhibitor rapa-
mycin (Rap), which predominantly inhibits mTORC1 [5]
(Figure 4b). The expression of HIFs was not influenced by. a) Western blot analysis of mTOR phosphorylation levels in OVSAYO
levels shown were based on band intensity quantification using
M1 in cells cultured under SSH for 16 h. Data shown are the mean
ured under SSH for 16 h in the presence or absence of rapamycin. d)
cted with siRNAs. Data shown are the mean (n = 3) ± SD. *P = 0.019,
pression in cells transfected with the indicated siRNAs and cultured
OVSAYO cells cultured as indicated. f) Effects of mTOR on mRNA levels
icted and cultured for 24 h. Cells were further cultured as indicated for
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Rap is not due to translational inhibition of HIFs. We also
confirmed that synergistic ICAM1 activation was de-
creased by mTOR silencing at mRNA and protein levels
(Figure 4d and e). Notably, unlike Rap treatment, HIF2
under SSH (but not HIF1) was downregulated when
mTOR was silenced (Figure 4e), implying that mTORC2
is responsible for HIF2 translation [6]. However, this de-
crease was not responsible for inhibition of synergistic
ICAM1 activation, as reduction of HIF2 levels was also
seen in cells cultured with FCS (Figure 4e).
We tested the effect of mTOR on the synergistic acti-
vation of other genes. Real-time RT-PCR revealed that
KLF6 and JUN induction was also repressed by mTOR
silencing under SSH (Figure 4f ). Furthermore, Sp1 levels
in OVSAYO cells were not significantly affected by
changes in the culture conditions (Additional file 2:
Figure S4a). Thus, the effect of mTOR is independent
of HIFs and Sp1 levels.
Activation of NFκB is crucial for synergistic ICAM1 induction
NFκB is activated during inflammation, hypoxia, and
irradiation and induces the expression of a variety of
genes, including ICAM1 [19,25-28]. Moreover, NFκB en-
hances HIF1 expression at the transcriptional level [29].Figure 5 NFκB activation is essential for synergistic ICAM1 activation
total RelA expression following ICAM1 induction in cells cultured under the
and hypoxia (1% O2), respectively. b) Diagram of the ICAM1 promoter regio
bar indicates the PCR amplicon for the ChIP assay. c) Quantitative ChIP ana
using cells cultured for 16 h under the indicated conditions. RelA binding levels
using IgG. Data shown are the mean (n = 3) ± SD. *P= 0.02. d) Effect of RelA on
conditions. Data are the mean (n = 3) ± SD. Inset: western blot analysis of ICAM1
SSH for 24 h. e) Western blotting against RelA and HIFs in lysates from cells tr
intensities quantified using ImageJ software.However, it is unclear whether NFκB contributes to the
unusual synergism of ICAM1 activation under SSH. We
found that the RelA subunit of NFκB became highly
phosphorylated under SSH in association with SSH-
specific ICAM1 induction (Figure 5a). Western blotting
of cytoplasmic and nuclear fractions revealed that RelA
was translocated from the cytoplasm to the nucleus under
SSH, subsequent to the expression of HIFs (Additional
file 2: Figure S4a). ChIP assays demonstrated that NFκB
binding to the ICAM1 promoter (Figure 5b) is highest
under SSH (Figure 5c), and real-time RT-PCR revealed
that ICAM1 expression at mRNA and protein levels
under SSH was markedly decreased by RelA knockdown
(Figure 5d). The relative expression pattern of HIFs can
be changed by RelA silencing (Figure 5e). Thus, NFκB
may influence ICAM1 expression through altered HIF
expression pattern. In contrast, experiments with the
same RNA samples showed that KLF6 and JUN expres-
sion under SSH was not influenced by RelA silencing
(Additional file 2: Figure S4b).
NFκB activation under SSH involves autonomous TNFα
production
We next investigated the mechanisms involved in NFκB
activation under SSH. We first evaluated the effect ofin OVSAYO cells. a) Western blot analysis of phospho-RelA (Ser536) or
indicated conditions for 16 h. N and H indicate normoxia (20% O2)
n and the positions of the Sp1, NFκB, and AP1 binding sites. A black
lysis of RelA binding to the ICAM1 promoter region by real-time PCR,
are represented as fold-increases relative to negative control experiments
synergistic ICAM1 activation in cells cultured for 16 h under the indicated
expression in cells transfected with indicated siRNAs and cultured under
ansfected with the indicated siRNAs. HIF levels shown are based on band
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dent upon this kinase activity. Western blotting showed
that RelA phosphorylation under SSH was decreased by
mTOR knockdown (Figure 6a). In contrast, phosphoryl-
ation levels under hypoxia with concurrent FCS treatment
were not influenced by mTOR knockdown (Figure 6a),
suggesting that mTOR associates with NFκB activity
under SSH.
To explore the mechanisms of NFκB activation, we
performed cDNA microarray analysis of genes synergis-
tically activated under SSH. We found the ratio of genes
with increased expression under SSH to that observed
under normoxia with FCS was > 3, while this ratio was < 2
when comparing gene induction under normoxia without
FCS and hypoxia with FCS (Additional file 2: Figure S4c
and Additional file 3: Table S2). To identify potential
mechanisms for these observations, we performed path-
way analyses of these genes using the Kyoto Encyclopedia
of Genes and Genomes database. We found that in
addition to ICAM1, tumor necrosis factor-α (TNFα) is
synergistically upregulated under SSH (Additional file 2:Figure 6 NFκB activation is associated with mTOR and autonomously
cells cultured under hypoxia. b) TNFα production in OVSAYO cells cultured
in cells transfected with siRNAs, as indicated. Data shown are the mean (n
in cells transfected with the indicated siRNAs and cultured under SSH for 2
e) Model of ICAM1 induction under SSH. Solid arrows, dashed arrows, and
induction, and active (phosphorylated) states, respectively.Figure S4d) and could potentially activate NFκB. We
found that TNFα protein levels were low under normoxia
and hypoxia with FCS stimulation, but were robustly in-
creased in OVSAYO cells cultured under SSH (Figure 6b).
Exposure to exogenous TNFα can induce ICAM1 in
cancer cells [27,30]. However, it is unclear how self-
produced TNFα affects SSH-specific gene activation in
CCC cells. Thus, we examined the effect of autono-
mously produced TNFα on the synergistic activation of
ICAM1 in OVSAYO cells by real-time RT-PCR. Syner-
gistic ICAM1 activation was reduced (Figure 6c) in
OVSAYO cells in which TNFα expression was com-
pletely blocked by RNAi (Figure 6d). Notably, RelA
phosphorylation levels under SSH were reduced by
TNFα knockdown (Figure 6d), although phosphorylation
under hypoxia plus FCS stimulation was not (Additional
file 2: Figure S4e). The amount of HIF2 (but not HIF1)
induced by SSH or hypoxia plus FCS was decreased by
TNFα silencing (Figure 6d and Additional file 2: Figure
S4e). Taken together, these data indicate that mTOR ex-
pression may correlate with TNFα under SSH.-produced TNFα. a) Effect of mTOR on RelA activation in OVSAYO
under SSH for 24 h. c) Effect of TNFα on synergistic ICAM1 activation
= 3) ± SD. *P = 0.018. Inset: western blot analysis of ICAM1 expression
4 h. d) Effect of TNFα on RelA activation under SSH in OVSAYO cells.
“p”s with bursts are indicative of the activation process, protein
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c-Jun expression contributes to the robust expression of
ICAM1, as c-Jun can regulate the ICAM1 promoter
(Additional file 2: Figure S5a). Various experiments dem-
onstrated that c-Jun does not contribute to synergistic
ICAM1 activation (Additional file 2: Figure S5). Thus,
we can summarize ICAM1 induction under SSH, based
on mechanisms described above (Figure 6e).
Serum factors responsible for synergistic gene activation
An unanswered question is the identity of serum factors
that are responsible for synergistic gene activation. We
initially found that the addition of growth factors does
not suppress synergistic ICAM1 activation (data not
shown). Thus, we tested whether synergistic ICAM1 in-
duction could be repressed by the addition of albumin
to serum-free culture media, as albumin is the most
abundant human plasma protein and plays multiple
roles in regulating blood functions [31]. We used an
albumin concentration of 44 μM, which corresponds toFigure 7 LCFAs are responsible for the synergistic activation of ICAM1
16 h with HP- or LP-Alb. Data shown are the mean (n = 2) ± SD. b) ICAM1 a
for 16 h. N, normoxia (20% O2); H, hypoxia (1% O2). Data shown are the me
presence or absence of HP-Alb and various LCFAs. Data shown are the me
in a) with or without albumin. e) Quantitative representation of d). Fluores
the mean (n = 6) ± SD. *P = 0.0002.protein level found in culture medium (2.9 mg/ml) with
10% FCS. We observed by real-time RT-PCR that ICAM1
mRNA levels under SSH were dramatically reduced in
cells cultured with bovine serum albumin compared with
those found without albumin (data not shown). We re-
peated these experiments with human albumin of differing
purities. Quantitative RT-PCR results revealed that syner-
gistic ICAM1 activation was markedly decreased in cells
cultured with low purity (LP) albumin (Figure 7a). How-
ever, ICAM1 induction in cells cultured with highly
purified (HP) albumin did not decrease compared with
the vehicle control (Figure 7a). This albumin-dependent
ICAM1 induction was also observed by RT-PCR using
reduced-albumin (red-alb) serum (Additional file 2: Figure
S6a and Figure 7b). However, parallel expression differ-
ences were not observed for VEGF (Figure 7b). These
results suggested that LP-albumin contains serum factors
responsible for suppression of the synergistic ICAM1 acti-
vation. We further showed that synergistic activation of
the KLF6 and JUN genes exhibits a similar expression. a) mRNA levels of ICAM1 in OVSAYO cells cultured under SSH for
nd VEGF mRNA expression levels in cells cultured with 1% serum
an (n = 3) ± SD. c) ICAM1 expression in cells cultured as in a) in the
an (n = 2) ± SD. d) Staining of neutral lipids in OVSAYO cells cultured as
cence areas were quantified using ImageJ software. Data shown are
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Figure S6b).
Long chain fatty acids are responsible for the suppression
of synergistic gene activation under SSH
Plasma albumin binds multiple molecules including
nutrients, hormones, and metabolites [31,32]. We next
examined the effect of long chain fatty acids (LCFAs) on
synergistic ICAM1 activation as the HP-albumin used in
this study is devoid of fatty-acids. Real-time RT-PCR
analysis revealed that a physiological concentration of
unsaturated LCFAs [33] (oleic and linoleic acids) largely
suppressed ICAM1 induction under SSH in OVSAYO
cells (Figure 7c). This decrease was further enhanced in
the presence of HP-albumin (Figure 7c). Weak or no
suppression of ICAM1 expression was observed after ex-
posing cells to physiological levels of saturated LCFAs
(palmitic and stearic acids) alone (Figure 7c). However,
ICAM1 induction was considerably suppressed when
cells were simultaneously cultured with these LCFAs
and HP-albumin.
We next determined the effect of LP- and HP-albumin
treatment on lipid levels in cells cultured under SSH as
LCFA uptake results in cytoplasmic lipid droplet accu-
mulation in cancer cells [34]. To examine the cellular
neutral lipid levels, cells were cultured in serum-free
medium in the presence or absence of LP- and HP-
albumin, and then stained with a neutral lipid marker,
the BODIPY fluorescent dye [34]. We detected stronger
BODIPY fluorescence when cells were cultured with LP-
albumin (Figure 7d and e), suggesting that cells are
starved of neutral lipids when cultured without LCFA.
This conclusion is supported by the detection of upregu-
lated of enhanced fatty acid synthase (Additional file 2:
Figure S6c), as expression of this enzyme is increased in
response to cellular lipid deficiency [35].
Effect of ICAM1 on CCC cell phenotype
ICAM1 expression within poorly vascularized necrotic re-
gions was observed in clinical CCC samples (Additional
file 2: Figure S7). Thus, we next examined whether ICAM1
confers a survival advantage to ovarian cancer cells under
SSH. Cloned OVISE cells stably transfected with scrambled
control (Scr-) or ICAM1-shRNA were prepared. The loss
of ICAM1 induction in OVISE cells under SSH was con-
firmed by western blotting (Figure 8a). We found that the
viability of ICAM1-silenced cells under SSH was more
significantly reduced compared to control shRNA cells
(Figure 8b and c). Similar results were obtained in ex-
periments using cell clones derived from OVSAYO cells
(Additional file 2: Figure S8). Thus, ICAM1 confers a
survival advantage to CCC cells exposed to SSH.
We performed western blot analysis of PARP-1 expres-
sion to ascertain whether ICAM1 can inhibit apoptoticcell death. We detected the cleaved form of PARP-1 only
in ICAM1-shRNA-transfected OVISE cells cultured under
SSH (Figure 8d). We next examined caspase activities in
shRNA-transfected cells cultured under the same SSH
conditions. We found that the activities of caspases-3
and -7 were elevated in ICAM1-shRNA-transfected cells
compared with control shRNA cells (Figure 8d). These
results suggested that ICAM1 confers an anti-apoptotic
effect under SSH.
ICAM1 is induced in vivo and confers tumor growth
advantage
Some studies have shown that ICAM1 expression im-
pairs progression of non-CCC ovarian cancers [30,36].
Thus, we further explored whether ICAM1 is induced
in vivo and if so, how ICAM1 expression affects tumor
growth. We first examined the proliferation of OVISE
cells stably transfected with Scr-shRNAs (Scr#1 and #2)
or ICAM1 shRNAs (ICAM1#1 and #2) under normoxia
plus FCS stimulation and confirmed that ICAM1
knockdown caused no significant effects (Additional file 2:
Figure S9a). We next subcutaneously injected Scr- and
ICAM1-shRNA transfected cells into NOD-SCID mice
(Figure 9a) and monitored subsequent tumor growths.
We found that the growth of xenograft tumors derived
from ICAM1-shRNA-transfected cells was inhibited
compared with that of control cells (Figure 9b). Western
blotting showed that ICAM1 levels in control tumors
were higher than those of tumors with ICAM1-shRNA
(Additional file 2: Figure S9b).
Hematoxylin and eosin (H&E) staining revealed tumor
tissues with typical CCC histological patterns of clear
cytoplasmic and dark nuclear staining (Figure 9c). Immu-
nohistochemistry (IHC) revealed that ICAM1 staining
was stronger in control tumors than in ICAM1-silenced
tumors (Figure 9d). IHC using antibodies against pimo-
nidazole-adducts (a severe hypoxia marker, hereafter re-
ferred to as pimo-adducts) and a milder hypoxia marker
(HIF1 and HIF2) revealed that the cell surface-staining
pattern of ICAM1 expression (Figure 9d, e, and Additional
file 2: Figure S10a) was clearly stronger within severely
hypoxic areas (Figure 9e). In situ hybridization experi-
ments provided further evidence of ICAM1 mRNA induc-
tion within severely hypoxic regions of the control tumors
(Additional file 2: Figure S10b). However, ICAM1 tran-
scripts were not detected within ICAM1-silenced tumors,
although these tumor tissues were also hypoxic (Additional
file 2: Figure S10c).
IHC staining further revealed that the number of
Ki67-positive cells within control tumors was greater
than that in ICAM1-silenced tumors (Figure 9f). However,
Ki67-positive cells were poorly detected within ICAM1-
positive areas within tumor tissues (Additional file 2:
Figure S10d and e), suggesting that ICAM1 indirectly
Figure 8 ICAM1 confers a survival advantage to CCC cells. a) Western blot analysis of ICAM1 expression in OVISE cells transfected with
shRNAs. N, normoxia for 24 h; H, 1% O2 for 24 h. b) MTS assays revealed the viability of OVISE cells cultured under serum-free conditions. c)
Relative survival rates of OVISE cells cultured as in b). The viabilities of cells cultured under SSH (estimated as in b) were normalized to viability
rates observed with cells cultured under normoxia without FCS. Data shown are the mean (n = 3) ± SD. *P = 0.036; **P = 0.001; ***P = 0.009;
****P = 0.007. d) Left: western blot of PARP-1 in OVISE cells. N, normoxia for 72 h; H, 1% O2 for 72 h. Right: caspase activities in OVISE cells cultured
under SSH for 96 h.
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viability of cells.
Lipid and vessel staining revealed that tissue lipid
levels were lower in vessel-poor regions in ICAM1-
positive xenograft tumor tissues (Figure 9g and Additional
file 2: Figure S11a), suggesting a directly proportional
correlation between lipid contents and vessel densities.
Immunofluorescence staining further showed that ICAM1
was strongly expressed within tissues in severely hypoxic
regions (Additional file 2: Figure S11b).
Discussion
Here, we demonstrated that Sp1 mediates the activation
of multiple genes in cooperation with HIFs. This tran-
scriptional activation is synergistically enhanced under
SSH, in contrast to the activation of authentic HIF-
dependent genes. We further showed that an insufficient
supply of LCFAs can lead to synergistic gene activation.
The ICAM1 protein is dramatically induced by this
mechanism and is critical for tumor growth in vivo, thusindicating a novel mechanism for adaptation to LCFA
starvation and hypoxia as a means to promote tumor
growth.
Evidence presented in this study suggests that direct
binding of both HIFs and NFκB to the ICAM1 promoter
region is essential for synergistic ICAM1 activation. Not-
ably, HIF2 binding appears to be mediated via inter-
action with Sp1. The synergistic activation of KLF6 and
JUN occurs independently of NFκB. This suggests that
transcriptional cooperation between Sp1, HIFs, and NFκB
promotes rigorous ICAM1 upregulation under lipid star-
vation and hypoxia through a distinct mechanism. In
addition, the question arises as to how NFκB may be acti-
vated under SSH, a condition where exogenous stimuli
such as cytokines are absent. Our study provides 2 an-
swers to this question. First, the activation is associated
with mTOR activity. This may correlate with earlier obser-
vations that, under non-hypoxic conditions, mTOR can
cause NFκB activation, leading to ICAM1 induction in
cancerous and normal cells [25,28]. Second, NFκB can be
Figure 9 (See legend on next page.)
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Figure 9 ICAM1 is inducible in vivo and confers a growth advantage to CCC tumors. a) Sites where NOD-SCID mice were injected with cells
expressing Scr-shRNA (#1 or #2) or ICAM1-shRNA (#1 or #2). b) Tumor volumes in mice injected with Scr-shRNA #1 or ICAM1-shRNA #1 (n = 9) or
Scr-shRNA #2 or ICAM1 shRNA #2 (n = 10). *P = 0.0006; **P < 0.0001; ***P = 0.002. c) H&E staining (scale bar: 100 μm). Immunohistochemistry of
ICAM1 d) Pimo-adduct and HIF1 e). Quantitation of ICAM1-positive cells within pimo (+) or (−) areas (n = 8). *P < 0.0001. Scale bar: 500 μm. f)
Immunohistochemistry of Ki67. Scale bar: 100 μm. Quantitation of Ki67 positive cells is shown (n = 8). *P < 0.0001. g) Lipid staining using frozen
sections of tumor tissue. Immunofluorescence of CD31 was also performed for vessels. Scale bar: 100 μm. The relationship between neutral lipid
staining with BODIPY and CD31 positivity was quantified (n = 10). *P < 0.0001. h) Hypothetical model of lipid starvation and hypoxia associated
with induction of genes of different categories in tumor tissues. Diffusion of LCFAs associated with high molecular weight albumin from the blood
stream is limited compared to that of smaller molecules (O2, glucose, and amino acids). Unlike (VEGF), (HO) and (GLUT1) genes, Sp1-dependent
genes such as ICAM1 may be efficiently up-regulated only under hypoxia with a limited LCFA supply, resulting in a survival advantage of cancer
cells to such a severe microenvironment.
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crine manner.
Recent evidence has shown that cancer cells utilize
aberrant mechanisms for energy metabolism [37]. Some
cancer cell types predominantly consume fatty acids
rather than glucose, relying on β-oxidation for energy
production [34,35]. In addition to their normal role as
an energy source, recent studies have revealed that
LCFAs may be involved in the tolerance of cancer cells
to various cellular stresses [35,38]. LCFAs exist in the
bloodstream in complex with albumin. It is possible that
the cellular uptake of LCFAs may be facilitated only in
association with albumin, resulting in their conversion
to neutral lipids (acyl-CoA derivatives) [39] in CCC cells.
In the present study, we showed that the removal of
LCFAs synergistically enhances Sp1-dependent activa-
tion of multiple genes under hypoxia. This effect appears
to be greater for unsaturated LCFAs than for saturated
LCFAs. This difference may be attributed to their roles
in transcriptional regulation in addition to altered metab-
olism pathways among LCFAs, as saturated and unsatur-
ated LCFAs could be differentially utilized as ligands for
some nuclear receptors [40]. It is necessary to uncover the
detailed mechanism(s) by which CCC cells sense LCFA-
starvation and hypoxia to trigger cellular signaling and
induce unusually high gene expression.
We found that ICAM1 enhances cell survival under
SSH at least in part through the inhibition of apoptosis.
This is distinct from the survival mechanism whereby
unsaturated LCFAs protect against UPR-dependent cell
death following ischemic conditions mediated by mTOR
activity [38]. Furthermore, ICAM1 promotes CCC tumor
growth in mice. Previous reports have found that ICAM1
induction during inflammation enhances eosinophil sur-
vival by activating cellular signaling mechanisms, resulting
in eosinophilia in asthma [41]. Thus, CCC cells might
similarly activate signaling cascades via ICAM1, enabling
cells to survive under severely hypoxic conditions. In add-
itional, ICAM1 is known to be overexpressed in cancer
cells where it recruits immune cells to promote tumor
progression [42]. Thus, immune cell-mediated mecha-
nisms may contribute to the acceleration of tumor growth,although it is not clear to what extent immune cells con-
tributed in our immunodeficient mouse model. Further-
more, our data contradict earlier reports showing that
ICAM1 suppresses ovarian cancer progression [30,36].
These discrepancies may be due to different histological
types or experimental settings tested.
The severity of hypoxia within tumor tissues varies
depending on the sparsity and aberrant nature of local
vasculatures, thus creating microenvironments with lim-
ited gradients of molecules supplied from the blood.
Diffusion-limited hypoxia occurs at ~100-μm distances
from blood vessels, and hypoxic severity in tissues in-
creases with increasing distances [43]. Given that the
sizes of O2, glucose, and amino acids are smaller than
that of LCFA (in complex with albumin), it is likely that
areas with lipid starvation, hypoxia, expression of HIFs,
and a nutrient supply exists in tumor tissues (Figure 9h).
In this case, tissue lipid levels may be used to define a
more severe hypoxia via Sp1 (Figure 9h). It was recently
reported that immunotherapy targeting ICAM1 is effect-
ive in treating multiple myeloma [44]. Thus, further clin-
ical investigations will likely support the validity of lipid
starvation and hypoxia as a target of cancer therapy.
Methods
Reagents
The following reagents were obtained from Sigma (St.
Louis, MO, USA): tunicamycin (T7765), HP-albumin from
human serum, fatty acid-free (A3782), LP-albumin from
human serum (A1653), palmitic acid (P0500), oleic acid
(O1008), linoleic acid (L1376), and stearic acid (S4751).
Rapamycin (553210) was purchased from (Millipore,
Temecula, CA, USA).
Cell culture
Human cancer cell lines used in this study were cultured
as previously described [8].
Transfection with expression vectors and siRNAs
Expression vectors and siRNAs targeting Sp1 and HIFs
were described previously [12]. We employed 2 individual
Koizume et al. Molecular Cancer  (2015) 14:77 Page 13 of 15siRNA sequences targeting each target protein. See
Additional file 4 for siRNAs.cDNA microarray analysis
Total RNA was isolated as previously described [8].
cDNA microarray analysis of genes activated in response
to CoCl2 stimulation in an Sp1-dependent manner was
performed by Takara (Shiga, Japan), using a human
whole genome array (Agilent Technologies, Santa Clara,
CA, USA). The effects of serum deprivation on the ex-
pression of genes under normoxic and hypoxic condi-
tions were analyzed by cDNA microarray analysis using
a NimbleGen Catalog Eukaryotic Gene Expression 385 K
Array (#5543886, Roche, Madison, WI, USA). Arrays
were scanned using a GenePix 4100A Microarray Scan-
ner (Axon Instruments, Union City, CA, USA), and data
were analyzed by Subio, Inc. (Kagoshima, Japan).Real-time RT-PCR analysis
mRNA levels were determined as previously described
[8,12]. See Additional file 4 for primer and probe sequences.
The mRNA expression levels of 18S ribosomal RNA were
measured using SYBR green-based detection [45].Protein quantification
Protein levels were quantified using the Micro BCA Protein
Assay Kit (23235; Thermo Scientific, Rockford, IL, USA).Western blotting
Western blotting was performed using Novex NuPAGE
4–12% Bis-Tris gels (Life Technologies, Carlsbad, CA,
USA). Detection was performed using ECL-Prime or
ECL-Advance (GE Healthcare, Buckinghamshire, UK). See
Additional file 4 for a description of the antibodies used.Reporter gene assays
Reporter gene assays were performed as previously
described [12]. Plasmid constructs encoding the ICAM1,
KLF6, and JUN 5′promoter regions used in ChIP assays
were prepared as previously described [12]. See Additional
file 4 for more details.ChIP assays
ChIP analyses were performed primarily as previously
described [8,12]. See Additional file 4 for more details.Preparation of cytoplasmic and nuclear fractions
Cytoplasmic and nuclear fractions were prepared using
an NE-PER Nuclear and Cytoplasmic Extraction Reagents
Kit (Thermo Scientific).Preparation of reduced-albumin serum
Albumin was removed from human serum (Takara Bio,
Shiga, Japan) using a Proteoprep Immunoaffinity Albu-
min & IgG Depletion Kit (Sigma).
Preparation of cells stably transfected with small hairpin
RNAs
Cells were stably transfected with short hairpin RNAs
(shRNAs) using pcDNA6.2-GW/miR, pLenti6/V5-DEST,
and the ViraPower Lentiviral Expression System (Life
Technologies). Several independent clones were isolated
by selecting cells in 10 μg/mL blasticidin. See Additional
file 4 for the shRNA sequences used.
Cell viability and caspase assays
Cell viabilities were estimated in MTS assays using the
CellTiter96 Aqueous One Solution Cell Proliferation
Assay (Promega, Madison, IL, USA). Caspase activities
were determined by performing Caspase-Glo assays
(Promega).
Xenograft tumor experiments
The institutional review board at the Kanagawa Cancer
Center Research Institute approved this study. OVISE
(1.5 × 107 cells) cell clones were subcutaneously injected
into 9 (for Scr-shRNA or ICAM1 shRNA #1) and 10 (for
Scr-shRNA or ICAM1 shRNA sh#2) NOD-SCID mice
(Charles River Laboratories Japan Inc., Yokohama, Japan).
Tumor growths were monitored by calculating tumor
volumes as the long diameter × (short diameter)2 × 1/2. A
Hypoxyprobe-1 Kit (Natural Pharmacia International,
Burlington, MA, USA) was used to detect tissue hypoxia.
Prior to tumor isolation, mice were injected intraperitone-
ally with pimonidazole-HCl solution (60 mg/kg). At
1 h post-injection, mice were sacrificed under general
anesthesia with isoflurane, and tumors were isolated for
further experiments.
Immunohistochemistry and immunofluorescence
Routinely processed formalin-fixed, paraffin-embedded
specimens were sectioned (4 μm thickness) and stained
with antibodies. Immunoreactivity was visualized by the
peroxidase-labeled amino acid polymer method, using
Histofine Simple Stain MAX-PO (Nichirei Co., Tokyo,
Japan) and the avidin-biotin-peroxidase complex method
(LSAB+; DakoCytomation Co., Tokyo, Japan), according
to the manufacturer’s instructions. Sections were coun-
terstained with H&E. In the case of ICAM1 immuno-
fluorescence, a secondary antibody (Alexa Fluor 488
anti-mouse IgG, Life Technologies) was used. Sections
were counterstained with DAPI using Prolong Gold
Antifade Reagent with DAPI (Life Technologies). Anti-
bodies against the following targets were used for IHC at
the indicated concentrations: ICAM1 (sc-8439, 4 μg/mL;
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1 Kit, 2.3 μg/mL; Hydroxyprobe), CD31 (6.7 μg/mL;
Dianova GmbH, Hamburg, Germany), HIF-1α (2.5 μg/mL;
BD Biosciences, San Jose CA, USA), HIF-2α (10 μg/ml;
NB100-122, Novus Biologicals, Littleton, CO), and Ki67
(1:25 dilution; BD Biosciences).
Microscopic detection of neutral lipid in cultured cells
and tumor tissues
Neutral lipid in cultured cells and tumor tissues was
detected by fluorescence microscopy using BODIPY
lipid probes (Life Technologies). Cultured OVSAYO
cells were washed twice with serum-free culture media
and treated with 25 μM of BODIPY lipid probes in
serum-free media for 5 min in a 37°C incubator. Cells
were then washed twice with serum-free media and used
for fluorescence detection. Images were acquired on an
OLYMPUS CKX41 microscope. Fluorescence areas were
quantified using ImageJ software (http://rsb.info.nih.gov/ij/).
For tumor tissues, frozen sections (8-μm thickness) of
xenograft tumors were treated with 100 μM of BODIPY
lipid probes (Life Technologies) in 50 mM Tris-HCl
(pH 7.6) for 30 min at ambient temperature. Tissues were
then washed twice with 50 mM Tris-HCl (pH 7.6), and
fluorescence detection was performed. Images were ac-
quired on a BZ-9000 fluorescence microscope (Keyence,
Osaka, Japan). Quantitative analysis of images was perfor-
med using equipped BZ-Analyzer software (Keyence).
Antibody labeling
Labeling of an anti-pimo antibody with Alexa Fluor dye
was performed using Zenon Mouse IgG Labeling Kits
(Life Technologies), according to manufacturer’s recom-
mended procedure.
In situ hybridization
In situ hybridization was performed using an RNAscope
2.0 FFPE Assay Kit (Advanced Cell Diagnostics, Hayward,
CA, USA) and an ICAM1 probe (402951, Advanced Cell
Diagnostics). Routinely processed formalin-fixed paraffin-
embedded specimens were sectioned (4-μm thickness)
and used in this study.
Clinical samples
FFPE tissues from surgically removed specimens were
prepared from patients of the Yokohama City University
Hospital under written agreements in the study, which
was approved by our institutional review board.
Statistics
Statistical significances were evaluated using 2-sided
Student’s t-tests for 2 data sets. P values < 0.05 were con-
sidered statistically significant.Accession numbers
The GEO database accession number for the microarray
dataset is GSE55565.
Additional files
Additional file 1: Table S1. Full list of genes identified by microarray
analysis described in Figure 1b. Genes appearing in this figure are underlined.
Additional file 2: Figure S1. a) ChIP analysis. b) ICAM1 expression in
OVISE cells. Figure S2. a) Real-time RT-PCR analysis of genes in OVSAYO
cells. b) Western blotting with OVSAYO cell lysates. c) Real-time RT-PCR
analysis using cells cultured under SSH. Western blotting was also performed.
Figure S3. a,b,c) Protein levels in OVSAYO cells. d) mRNA levels were analyzed
for cells cultured with or without Tun. V: vehicle. e) Effect of Tun on the
ICAM1expression. Figure S4. a) Western analysis of indicated fractions of
OVSAYO cells. b) Effect of RelA on the activation of genes. c) Venn diagram
representation of genes. d) Heat map representation of gene expressions. e)
Western analysis of cells transfected with siRNA. Figure S5. a) AP1 and NFκB
bind to the promoter region. b) Quantitative ChIP analysis of c-Jun binding
to the ICAM1 promoter. c) c-Jun expression in OVSAYO cells. d) Real-time
RT-PCR analysis. Cells transfected with siRNAs were cultured under SSH.
c-Jun expression in siRNA transfected cells is also shown. Figure S6. a)
Approximately 80% of albumin was removed from human serum, resulting
in reduced-albumin serum. b) Real-time RT-PCR analysis of indicated genes.
c) Expression of fatty acid synthase (Fasn) in OVSAYO cells. Figure S7. a)
ICAM1 immunocytochemistry in OVISE cells transfected with Scr- and
ICAM1-shRNA #1. Cells were cultured under SSH. b) H&E staining and IHC
using a surgically removed specimens from CCC patients. Figure S8. a)
Western blot analysis, b,c) MTS assay. Figure S9. a) Proliferation of OVISE
cells transfected with shRNAs. b) ICAM1 expression in tumor tissues.
Figure S10. a,c,d) IHC using tumors transfected with Scr-shRNA#2. In situ
hybridization is also shown. b) In situ hybridization using tumors transfected
with Scr-shRNA#2. e) Quantitation of Ki67-positive cells. Figure S11. a)
Immunofluorescence and neutral lipid staining, using tumor tissues
transfected with Scr-shRNA#2. DAPI was used for counter staining of nuclei.
Bar = 100 μm. b) Immunofluorescence using tumor tissues transfected with
Scr-shRNA#2. Bar = 100 μm.
Additional file 3: Table S2. Full list of genes (probes) identified by
microarray analysis as shown in Additional file 2: Figure S4c.
Additional file 4: Supplementary informations. Reagents and
experimental procedures [8,12,46].
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